PHVS: Deucrictibant shows injectable-like efficacy in HAE, with robust launch and global plans underway
Deucrictibant achieved high efficacy in severe HAE patients, with a strong safety profile and rapid onset. Launch preparations are advanced, targeting both on-demand and prophylactic markets, with global expansion under evaluation. Key clinical and regulatory milestones are expected in the next yea…